Retinopathy of Prematurity: Do We Still Have a Problem? The Charles L. Schepens Lecture | Neonatology | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens, I: preliminary report.  Am J Ophthalmol. 1942;25:203-204Google Scholar
Crosse VM, Evans PJ. Prevention of retrolental fibroplasia.  AMA Arch Ophthalmol. 1952;48(1):83-8714932566PubMedGoogle ScholarCrossref
Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness.  J AAPOS. 1999;3(1):26-3210071898PubMedGoogle ScholarCrossref
Gilbert C, Fielder A, Gordillo L,  et al; International NO-ROP Group.  Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs.  Pediatrics. 2005;115(5):e518-e52515805336PubMedGoogle ScholarCrossref
Gilbert C. Retinopathy of prematurity: epidemiology.  J Community Eye Health. 1997;10(22):22-24 Accessed May 27, 2011.Google Scholar
Reddy SC, Tan BC. Causes of childhood blindness in Malaysia: results from a national study of blind school students.  Int Ophthalmol. 2001;24(1):53-5911998890PubMedGoogle ScholarCrossref
Haddad MA, Sei M, Sampaio MW, Kara-José N. Causes of visual impairment in children: a study of 3,210 cases.  J Pediatr Ophthalmol Strabismus. 2007;44(4):232-24017694828PubMedGoogle Scholar
Rahi JS, Sripathi S, Gilbert CE, Foster A. Childhood blindness in India: causes in 1318 blind school students in nine states.  Eye (Lond). 1995;9(pt 5):545-5508543070PubMedGoogle ScholarCrossref
Kello AB, Gilbert C. Causes of severe visual impairment and blindness in children in schools for the blind in Ethiopia.  Br J Ophthalmol. 2003;87(5):526-53012714383PubMedGoogle ScholarCrossref
Cryotherapy for Retinopathy of Prematurity Cooperative Group.  Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 5 1/2 years after randomization.  Arch Ophthalmol. 1996;114(4):417-4248602778PubMedGoogle ScholarCrossref
Good WV, Hardy RJ, Dobson V,  et al; Early Treatment for Retinopathy of Prematurity Cooperative Group.  The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity Study.  Pediatrics. 2005;116(1):15-2315995025PubMedGoogle ScholarCrossref
Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith BT. Retinopathy of prematurity: the life of a lifetime disease.  Am J Ophthalmol. 2006;141(1):167-17416386993PubMedGoogle ScholarCrossref
Baker PS, Tasman W. Optical coherence tomography imaging of the fovea in retinopathy of prematurity.  Ophthalmic Surg Lasers Imaging. 2010;41(2):201-20620307038PubMedGoogle ScholarCrossref
Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity.  Am J Ophthalmol. 2008;145(6):1090-109418374298PubMedGoogle ScholarCrossref
 US Census Bureau Estimates. US Census Bureau Web site. Accessed May 27, 2011
 US Census Bureau International Data Base (IDB). Accessed May 27, 2011
Hurley BR, McNamara JA, Fineman MS,  et al.  Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years.  Retina. 2006;26(7):(suppl)  S16-S1716946671PubMedGoogle ScholarCrossref
Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.  Semin Ophthalmol. 2007;22(2):109-12517564934PubMedGoogle ScholarCrossref
Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.  Retina. 2008;28(6):831-83818536599PubMedGoogle ScholarCrossref
Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.  Invest Ophthalmol Vis Sci. 2009;50(10):4905-491619407010PubMedGoogle ScholarCrossref
Silverman WA. Retrolental Fibroplasia: A Modern Parable. New York, NY: Grune & Stratton; 1980
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network.  Target ranges of oxygen saturation in extremely preterm infants.  N Engl J Med. 2010;362(21):1959-196920472937PubMedGoogle ScholarCrossref
Avery RL, Pearlman J, Pieramici DJ,  et al.  Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.  Ophthalmology. 2006;113(10):1695.e1-1695.e1517011951PubMedGoogle ScholarCrossref
Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity.  Br J Ophthalmol. 2008;92(11):1437-143818952651PubMedGoogle ScholarCrossref
Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity.  Ophthalmology. 2009;116(3):513-51819157560PubMedGoogle ScholarCrossref
Darlow BA, Gilbert C, Quinn GE,  et al.  Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity.  Br J Ophthalmol. 2009;93(7):98619553518PubMedGoogle ScholarCrossref
Special Article
Aug 2011

Retinopathy of Prematurity: Do We Still Have a Problem?The Charles L. Schepens Lecture

Author Affiliations

Author Affiliations: Department of Ophthalmology, Jefferson Medical College, Thomas Jefferson University, and Wills Eye Hospital, Philadelphia, Pennsylvania.

Arch Ophthalmol. 2011;129(8):1083-1086. doi:10.1001/archophthalmol.2011.192

Objective To assess the present-day prevalence of retinopathy of prematurity (ROP) worldwide.

Methods A search of the literature was conducted to better define the worldwide experience with ROP. An interview was also conducted with 2 schools for the blind, Overbrook in Philadelphia, Pennsylvania, and Perkins in Watertown, Massachusetts. The study also is based on personal experience with ROP over the last 49 years.

Results Worldwide, the prevalence of ROP is on the rise in developing countries, and some of those ROP-affected premature infants are heavier than 1500 g. In western countries, extremely low-birth-weight infants (≤1000 g) are also surviving. Currently, the Overbrook School for the Blind has 11 of 55 children between the ages of 3 and 5 years with ROP (20%). The Perkins School has 34 of 200 children from birth to age 3 years with ROP (17%). During 2009, 47 babies had laser treatment for ROP in the neonatal intensive care unit of Jefferson Medical College by physicians from Wills Eye Hospital. Twenty-four infants had been identified in a screening of 591 patients (4.1%). The other 23 had been referred in for treatment. In 2009, we had 187 outpatient visits related to ROP ranging from 6 months to 67 years of age.

Conclusions Because more and more extreme low-birth-weight infants are surviving in western countries and because of the rising numbers of surviving premature infants in emerging nations, we may be on the verge of an ROP epidemic.